Studies demonstrate improved safety results achieved with investigational drug for hep B
Studies demonstrate that tenofovir alafenamide (TAF) improves patient safety while maintaining efficacy in patients with chronic hepatitis B virus (HBV) infection compared to tenofovir disoproxil fumarate (Viread, TDF).
Leave a Reply